Latest Lipid Guidelines in Perspective

Slides:



Advertisements
Similar presentations
Figure 1: Questions included in questionnaire
Advertisements

Statin Myopathy (AHA/ACC/NHLBI)
PCSK9 Regulates LDLR Turnover Through Increased Intracellular Degradation.
The Latest Lipid Guidelines:
Recommendation of NLA Expert Panel on Treatment With PCSK9 Inhibitors
PCSK9 Inhibitors and Cardiovascular Outcomes Trials
Diabetic Dyslipidemia in Practice
Updates and Perspectives in Diabetic Dyslipidemia
Cholesterol, CV Events, and PCSK9 Inhibitors Highlights From the AHA
PCSK9 Inhibitors Post-CVOTs
New Guidelines to Prevent SCD: What You Need to Know
Statin Selection in the Elderly
LDL Established Target for Cardiovascular Risk
Current Dyslipidemia Management Guidelines Residual Risk.
An Endocrinology Clinic in Dyslipidemia
Use of the Coronary Artery Calcium Score in Discussion of Initiation of Statin Therapy in Primary Prevention  Erin D. Michos, MD, MHS, Michael J. Blaha,
Diabetes and Dyslipidemia
A multicenter, double-blind, randomized study to establish the clinical benefit and safety of ezetimibe/simvastatin tablet (vytorin) vs simvastatin.
Patient Presentation. Patient Presentation PRIMO Study Incidence of Muscle Adverse Effects.
PCSK9 Loss-of-function Mutations PCSK9-Mediated Degradation of LDL-R.
GAUSS-3 Trial design: Patients with objective evidence of intolerance to statin agents were randomized in a 2:1 fashion to either evolocumab 420 mg subcutaneously.
Cholesteryl Ester Transfer Protein Inhibitors
Moderate-Intensity Statins for Dyslipidemia: How to Treat Today?
American Heart Association Scientific Sessions
Obesity and Dyslipidemia: How Would You Treat?
Statins and the Elderly Patient
Patient Presentation. Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?
Beyond Statin Therapy.
LDL-C Goals. The Patient With Difficult-to-Treat Hypercholesterolemia: Is Everything Under Control?
Statin Class in Session
An Update on PCSK9 Inhibitors
Evaluating LDL-C Recommendations
New Pathways in Lipid Care
What's New in Dyslipidemia?
Statin Class in Session
PCSK9 Inhibitors and Cardiovascular Outcomes
PCSK9 Inhibitors – A Leap in the Evolution of Dyslipidemia Management?
A Patient Journey Through Statin Intolerance
Improving Appropriate Access to PCSK9 Inhibitors
Patient Selection, Pharmacoeconomics, and PCSK9 Inhibitors
New LDL-C Lipid Targets
A PCP's Guide to Dyslipidemia
Radical New Concepts in Lipid Management
Clinicians' Corner in Dyslipidemia
Updates in Cardiovascular Medicine
WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?
Dallas Heart Study Lipid Characteristics of Blacks With Nonsense Mutations in PCSK9
Addressing Access to PCSK9 Inhibitors: Tips and Tools for Practicing Clinicians.
Program Goals. Program Goals LDL Established Target for Cardiovascular Risk.
Evaluating BTK Inhibitors in CLL
PCSK9 Mutations PCSK9 Loss-of-function Mutations.
Glucose Management and Statin Therapy
LDL Cholesterol.
How to Optimize Cholesterol Management in High-Risk CV Patients
Approximate Dose Equivalency of Statin LDL-C Efficacy.
Reducing Risk for CV Outcomes
Practical Strategies for Getting Patients With Diabetes to Lipid Goal
A Family Affair.
New Lipid-Lowering Guidelines
Lipid Updates From Spring 2019
New Lipid-Lowering Therapies
An Update on PCSK9 Inhibitors
Glucose Management and Statin Therapy
PCSK9 Inhibitors and Statin Intolerance
Updates on Dyslipidemia
Achieving Lipid Targets With PCSK9 Inhibition
Intensive Lowering of Low-Density Lipoprotein Cholesterol Levels for Primary Prevention of Coronary Artery Disease  Dean G. Karalis, MD  Mayo Clinic Proceedings 
Lipids, the Heart, and the Kidney
PCSK9 Inhibitors and Real-World Evidence
Shared-Decision Making in Dyslipidemia
Presentation transcript:

Latest Lipid Guidelines in Perspective

What's New in the 2018 Cholesterol Guideline?

10-Year Risk Score

10-Year Risk for ASCVD[a]

Beyond Statins -- Getting LDL to Goal

Identify Patients With Statin Intolerance

Alirocumab and Evolocumab

Guideline Term Update

GAUSS-3 Study Design 2 Double-Blind Phases

GAUSS-3 Takeaway Points

Nonstatin Treatments

Risk-Enhancing Factors for Primary Prevention*

10-Year Risk Calculation Is Just the Beginning

Risk of Elevated Lp(a) in General Population

Statins Increase Coronary Calcium

CAC Measurement Recommendations

CAC -- Use With Caution

Fasting Lipid Profiles

Who Gets Treated With a PCSK9 Inhibitor

Normal and Abnormal Lipid Values in Childhood

Key Take-Home Messages

Shared Clinician-Patient Decision Making

Abbreviations

Abbreviations (cont)

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.